Special Issue Of Point Of Care Highlights Patient Safety and Avoiding Medical ErrorsMany medical tests that once required sending samples to a laboratory and waiting for results can now be performed quickly at the patient bedside. Since these point-of – care testing technologies into patient care into patient care, special attention is required to protect the safety of patients and to prevent medical errors, according to this month special issue of Point of Care: The Journal of near – patient Testing & Technology.
As required POCT routine, special attention to patient safety Becomespoint-of-care testing, the joint laboratory rapidly rapidly obtained on or near the bedside or in the doctor’s office more sophisticated and widespread that. Special issue presents contributions from the laboratory manager, ‘POC coordinators ‘and other professionals on the front lines working to ensure that POCT are securely integrated into clinical care.
Several articles provide informative examples of errors that have arisen with the widespread implementation of POCT technology.C the primary outcome the study the loss of weight be addition investigated other effects, comparing the %age of patients losing the at least 5 percent or 10 percent of their baseline bodyweight and the effect on HbA1c layers. Reducing in HbA1c has been shown to delay or prevent diabetes issues with, connected to how damage to your eyes, kidneys and nerves. Screening of patient be should process engineering and dose to start this month. Other details , see.. Phase 2 trial style evaluated three different doses of Nastech which PYY3-36 Nasal Spray as compared to placebo and sibutramine ), a commercial available oral weight loss drug, with the primary endpoint being weight loss. Patients in said active treat arm PYY company PYY3-36 nasal spray or as nasal sprays placebo three times per day of a meal over the 24 – week period.
Nastech Pharmaceutical Company announced start of a phase 2 trial to PYY3 36 Nasal Spray for the treat obesity.
Nastech Pharmaceutical Company in Inc. on the start of an Phase 2 clinical study evaluating of the company PYY3-36 Nasal Spray known obese patients. The trial will registered mail some 500 obese patients for six months, randomized, placebo – controlled dose escalation study by weight loss as the primary endpoint.